Caris Life Sciences (CAI) Share-based Compensation (2024 - 2026)
Caris Life Sciences' (CAI) quarterly Share-based Compensation came in at $56000.0 in Q1 2026, down 99.62% year-on-year from $14.7 million in Q1 2025, and up 100.11% quarter-over-quarter from -$52.8 million in Q4 2025.
Caris Life Sciences (CAI) Share-based Compensation (2024 - 2026) Analysis & Trends
Caris Life Sciences' Share-based Compensation history runs 3 years deep, the most recent figure standing at $56000.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 99.62% year-over-year to $56000.0 in Q1 2026; TTM through Mar 2026 was -$10.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.9 million, up 431.17% from the prior year.
- Share-based Compensation advanced to $56000.0 in Q1 2026 per CAI's latest filing, from -$52.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $55.0 million in Q3 2025 and bottomed at -$52.8 million in Q4 2025.
- The 3-year median for Share-based Compensation is $56000.0 (2026), against an average of -$615857.1.
- Biggest YoY gain for Share-based Compensation was 714.79% in 2025; the steepest drop was 7381.1% in 2025.
- Year by year, Share-based Compensation stood at $725000.0 in 2024, then slumped by 7381.1% to -$52.8 million in 2025, then jumped by 100.11% to $56000.0 in 2026.
- Per Business Quant, the three latest CAI Share-based Compensation figures stand at $56000.0 (Q1 2026), -$52.8 million (Q4 2025), and $55.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Caris Life Sciences | 4.42 Bn | 3.60 Bn | 214.23 Mn | 56,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | -52.79 Mn |
| Dec 31, 2025 | -52.79 Mn |
| Sep 30, 2025 | 54.98 Mn |
| Sep 30, 2025 | 54.98 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Mar 31, 2025 | 14.69 Mn |
| Mar 31, 2025 | 14.69 Mn |
| Dec 31, 2024 | 725,000.00 |
| Dec 31, 2024 | 725,000.00 |
| Sep 30, 2024 | -8.94 Mn |
| Sep 30, 2024 | -8.94 Mn |